Pall Corporation Secures Multi-Million Dollar Contract With Exothera

Rhea-AI Summary

Pall Corporation has secured a contract valued at over $7 million with Exothera S.A. to develop a 2000L suspension-based manufacturing platform. This platform will utilize Allegro STR single-use bioreactors for producing viral vectors essential for gene therapies and vaccines. Exothera is expanding its capacity with new GMP facilities in Brussels, enhancing its production capabilities for viral vector platforms. Pall's expertise in scalable processes will support Exothera's goals, addressing increasing market demands highlighted by the COVID-19 pandemic.

Positive

• Secured a contract worth over $7 million with Exothera, indicating strong business growth.
• Developing a 2000L suspension-based manufacturing platform using Allegro STR bioreactors, enhancing production capabilities.
• Collaborating with Exothera, which is expanding its GMP facilities, indicating industry confidence and demand.

Negative

• None.

PORT WASHINGTON, N.Y., July 1, 2021 /PRNewswire/ -- Pall Corporation, a global leader in filtration, separation and purification, today announced a new contract worth more than $7M with full-service contract development and manufacturing organization (CDMO) Exothera S.A. 

The new contract with Pall will establish a suspension-based manufacturing platform of up to 2000L, using a range of technologies including Allegro™ STR single-use bioreactors. The new installation allows for the production of a variety of viral vectors for gene therapies and viral vector-based vaccines.

Exothera recently announced a significant expansion of its manufacturing capabilities, with two new state-of-the-art Good Manufacturing Practice (GMP) facilities built at the company's Jumet site near Brussels, Belgium. The new facilities, which are roughly 92,000 square feet and include a variety of functions from research and development to commercial production, will begin GMP production this summer.

Clive Glover, General Manager, Gene Therapy at Pall Corporation, said: "There is a strong pipeline of viral vector-based gene therapies and vaccines and the importance of rapidly realizing industrial-scale production for these vaccines and therapies has been brought into sharp focus by  COVID-19. Pall has considerable process development expertise from working with many of the industry leaders to develop scalable upstream and downstream processes. We're thrilled to bring this experience to support Exothera as they expand their manufacturing capabilities."

The gene therapy and vaccine industries are facing complex challenges when scaling up vector-based processes. According to Vasily Medvedev, head of development at Exothera, the company selected the Pall end-to-end solution based on its flexibility and its capability to scale up processes quickly and efficiently.

"We selected Pall for their technological excellence and strong track record in the gene therapy and vaccines industries, as well as the level of support the team provides," explained Medvedev. "They offer a robust and cost-effective single-use solution."

Christian Borgniet, Chief Operating Officer of Exothera, added: "Compared to other suspension solutions, Pall's STR bioreactors are well-suited and could be adapted, if needed, to the perfusion mode, allowing higher growth and density of cells. We are pleased to establish this partnership with a very supportive company that is willing to transfer its expertise."

About Pall Corporation
Pall Corporation is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The Company's engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide. For more information visit https://www.pall.com.

Or follow us on social media:

LinkedIn     Twitter     Facebook

Corporate Media Contact:
Pall Corporation
Amanda Comeau
Director, Corporate Communications
(508) 330-0811

About Exothera SA
Exothera is a viral vector CDMO (contract manufacturing and development organization) leveraging standard and innovative bioproduction platforms to rapidly deliver affordable viral vector-based vaccines and cell and gene therapies. As a Univercells company, Exothera capitalizes on novel manufacturing technologies and best-in-class bioprocessing expertise to provide bespoke process optimization and GMP clinical and commercial production of viral vectors. Based on its extensive technology expertise, Exothera selects technologies to optimally answer customer needs for cost-effective and agile viral vector manufacturing.

LinkedIn: https://www.linkedin.com/company/exothera / Website: www.exothera.world

View original content to download multimedia:https://www.prnewswire.com/news-releases/pall-corporation-secures-multi-million-dollar-contract-with-exothera-301323764.html

SOURCE Pall Corporation

FAQ

What is the value of Pall Corporation's contract with Exothera?

Pall Corporation secured a contract valued at over $7 million with Exothera.

What technologies will Pall Corporation use in its contract with Exothera?

Pall will establish a suspension-based manufacturing platform using Allegro STR single-use bioreactors.

Where is Exothera's new manufacturing facility located?

Exothera's new manufacturing facility is located in Jumet, near Brussels, Belgium.

Why did Exothera choose Pall Corporation for this contract?

Exothera chose Pall for its technological excellence and strong track record in the gene therapy and vaccine industries.

What are the implications of Pall's contract for the gene therapy market?

The contract highlights the rising demand for viral vector manufacturing, driven by advancements in gene therapies and vaccines.